天士力子公司TSL2109胶囊获得药物临床试验批准通知书

Core Viewpoint - Tianjin Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the dual targets, blocking the tumor cell cycle and inducing apoptosis in tumor cells [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]